6533b854fe1ef96bd12ae001
RESEARCH PRODUCT
Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia--initial results.
Hermann HeimpelKarin KolbeArnold GanserGerhard HeilLothar BergmannParis S. MitrouDieter HoelzerJ.t. FischerWolfgang HeitGeorg MaschmeyerC. Hubersubject
OncologyAdultMalemedicine.medical_specialtymedicine.medical_treatmentMaintenance therapyhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineSecondary Acute Myeloid LeukemiaIdarubicinHumansEtoposideAgedEtoposideChemotherapybusiness.industryRemission InductionCytarabineMyeloid leukemiaHematologyGeneral MedicineMiddle AgedGranulocyte colony-stimulating factorLeukemia Myeloid AcuteMyelodysplastic SyndromesImmunologyCytarabineInterleukin-2FemalebusinessIdarubicinmedicine.drugdescription
Aggressive chemotherapy of advanced myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) evolving from MDS, subacute AML and secondary AML has usually been associated with low complete remission (CR) rates, a high incidence of early death, and low disease-free survival. We therefore have initiated a phase-III trial of aggressive chemotherapy consisting of idarubicin, cytosine arabinoside, and VP-16 to improve the CR rate. Each chemotherapy cycle is followed by G-CSF to accelerate neutrophil recovery and to reduce the incidence of infections. Until now, 19 patients with high-risk AML have been entered. The CR rate is 47%, with only one death during induction. Patients achieving CR are randomized to receive either high-dose or low-dose interleukin-2 to eliminate residual leukemic cells and to prolong the duration of remission.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1993-03-01 | Annals of hematology |